… of a monoclonal antibody in an infectious disease in humans. Monthly intramuscular
injections of 15 mg/kg of palivizumab reduced the incidence of hospitalization because of a RSV …

… that palivizumab was an effective monoclonal antibody for … of palivizumab reduced the
incidence of RSV hospitalization compared … This decrease compared to the 41% decrease in RSV …

… on palivizumab, a humanized RSV monoclonal antibody, marks … % decrease in RSV
hospitalization in children who received … that palivizumab can prevent RSV-related hospitalization …

… It found that palivizumab reduces hospitalization due to RSV infection at 2-year follow‐up (…
of RSV infection, a next generation of monoclonal antibody prophylaxis—nirsevimab—that is …

… Palivizumab prophylaxis reduces hospitalization due to … prophylaxis among infants
and young children at increased risk of hospitalization for respiratory syncytial virus infection. …

… Humanized monoclonal antibodies (palivizumab) have been … and effectiveness of palivizumab
in children hospitalized for acute … of palivizumab could be effective to reduce RSV-related …

… (RSV) is the leading cause of hospitalizations in infants worldwide. Palivizumab, a humanized
monoclonal antibody against the … Palivizumab prophylaxis reduces hospitalization due to …

… Only 2.3% of children receiving palivizumab prophylaxis were hospitalized with RSV lower
… using palivizumab humanized monoclonal antibody for protection from RSV lower respiratory …

… Objective Palivizumab is a humanized monoclonal antibody … lower respiratory tract infection
(LRTI) caused by respiratory … risk of hospitalization for respiratory syncytial virus infection. …

… Home-care prophylaxis with palivizumab was associated with reduced hospitalization rates.
… ; MedImmune, Gaithersburg, MD, USA), a humanized murine monoclonal antibody with …